Progress is highlighted by the acquisition of both the first Food and Drug Administration (FDA) licence and marketing authorization by the European Commission, for oncolytic virotherapy—talimogene laherparepvec—a herpes simplex virus that has been genetically engineered to express granulocyte macrophage colony stimulating factor (GM-CSF) to treat advanced melanoma. Here, CSF2 is linked to melanoma.